Kairos Pharma Ltd's Business Segments

The company is a clinical-stage biopharmaceutical firm developing therapeutics for cancer patients, focusing on immune suppression and drug resistance. Its portfolio includes antibodies and small molecules targeting prostate cancer, lung cancer, breast cancer, and glioblastoma. The company applies molecular insights into therapeutic resistance and immune suppression to develop novel drugs. Its seven-drug portfolio comprises five pre-clinical or clinical-stage candidates targeting immune response and two therapeutic agents developed by its subsidiary, Enviro Therapeutics, Inc., which it acquired in 2021. These agents address resistance to cancer therapies and include technologies targeting CD105 and mitochondrial DNA depletion. The lead drug, ENV 105, targets endoglin to overcome resistance mechanisms and is in Phase 1 and Phase 2 trials. Another agent, ENV 205, is in pre-clinical development and targets mitochondrial DNA for chemotherapy resistance and cachexia. The pipeline also includes KROS 101, 102, 201, 301, and 401, with KROS 201 being a T cell therapy for glioblastoma. Clinical trials have demonstrated a 62% clinical benefit rate in a Phase 2 prostate cancer trial combining ENV 105 with hormone therapies enzalutamide and abiraterone, including in patients resistant to these therapies.

The Company operates as a clinical-stage biopharmaceutical business focused on developing immunotherapy and cell therapies for cancer treatment. It functions as a single reportable segment. The Chief Executive Officer serves as the Chief Operating Decision Maker (CODM), reviewing financial information and allocating resources based on net income (loss). Key segment expenses include research and development (excluding officer compensation), officer compensation and wages, insurance, stock-based compensation, and operating expenses such as external professional services and administrative costs. Net income (loss) is used to assess financial performance.